BWMX Betterware de México, S.A.P.I. de C.V.
Betterware de México, S.A.P.I. de C.V. operates as a direct-to-consumer selling company in the United States and Mexico. It operates through Home Organization Products; and Beauty and Personal Care Products segments. The Home Organization Products segment provides a portfolio of products comprising kitchen and food preservation; home solutions; bedroom; bathroom; laundry and cleaning; wellness; and technology and mobility. The Beauty and Personal Care Products segment offers fragrances, color, skin care products, and toiletries. It sells its products through catalogues, as well as distributes through a network of distributors, associates, leaders, and consultants to the end customers. Betterware de México, S.A.P.I. de C.V. is headquartered in El Arenal, Mexico. The company operates as a subsidiary of Campalier S.A. de C.V.…
Industry Peers
Specialty RetailKey Statistics
About Betterware de México, S.A.P.I. de C.V. (NYSE: BWMX)
›
Betterware de México, S.A.P.I. de C.V. (NYSE: BWMX) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Specialty Retail industry, part of the Consumer Cyclical sector, and reports about 4,373 employees.
The shares were at 17.14 USD on 13 November 2026, up 28.7% over 52 weeks. Its 52-week range is 13.41 USD to 19.79 USD: the price is 13.4% below the high and 27.8% above the low.
At a market capitalisation of 638.36M USD, it trades at 8.5 times trailing earnings and 6.6 times forward earnings. The median trailing P/E of its 20 largest Specialty Retail peers is 17.0, a discount of 50% for BWMX. It pays a dividend yielding 7.95% (it pays out 63% of its earnings), against a median of 2.58% among the dividend payers in that peer group.
Betterware de México, S.A.P.I. de C.V. reports return on equity of 77.9%, an operating margin of 16.5% and revenue up 43.1% year over year.
Its debt exceeds its cash by 6.89B MXN, a debt-to-equity ratio of 3.28. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 3 analysts cover the stock; their mean price target of 29.26 USD is 70.7% above the current price. The next earnings report is expected on 25 February 2027.